FIELD: chemistry.
SUBSTANCE: invention relates to organic chemistry and specifically to a quinoline derivative of formula (A) or a pharmaceutically acceptable salt thereof, wherein Z is selected from O or -NH-; W1 is N; W2 is CRb; W3 is CRc; R2 is selected from hydrogen and R3 is selected from methyl; or R2 is selected from hydrogen and R3 is selected from ethyl; or R2 is selected from hydrogen and R3 is selected from isopropyl; or R2 and R3 both are selected from methyl; or R2 and R3 both are selected from ethyl; or R2 and R3 both are selected from n-propyl; Rb is selected from a group comprising hydrogen, halogen, C1-C3-alkyl, C3-cycloalkyl, C6-aryl, heteroaryl selected from pyridine, where said alkyl, aryl or heteroaryl is independently and optionally substituted with one to three substitutes selected from a group comprising halogen, cyano, oxo, C1-alkyl, C1-halogenalkyl, -ORd; Rc is selected from a group comprising halogen, C1-C3-alkyl, C3-cycloalkyl, C6-aryl, heteroaryl selected from pyridine, where said alkyl, aryl or heteroaryl is independently and optionally substituted with one to three substitutes selected from a group comprising halogen, cyano, oxo, C1-alkyl, C1-halogenalkyl, -ORd; Rd is selected from a group comprising hydrogen, C1-C3-alkyl, C3-C4-cycloalkyl, where said alkyl is independently and optionally substituted with two to three substitutes, which are halogen; X, Y are hydrogen; when Z is O, R4 is hydrogen. Invention also relates to a method of producing a compound of formula (A) and use thereof.
EFFECT: obtaining a novel quinoline derivative which inhibits URAT1 and is useful in treating gout, recurrent gout, gouty arthritis, hyperuricemia.
9 cl, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHBITORS | 2007 |
|
RU2451015C2 |
| MULTIFUNCTIONAL QUINOLINE DERIVATIVES AS ANTINEURODEGENERATIVE AGENTS | 2013 |
|
RU2642466C2 |
| CYANOQUINOLINE DERIVATIVES | 2011 |
|
RU2600928C2 |
| 3-AMINO-PYRIDINE DERIVATIVES FOR TREATING METABOLIC DISORDERS | 2007 |
|
RU2460729C2 |
| THERAPEUTIC COMPOUNDS AND COMPOSITIONS AND METHODS OF USING THEM | 2018 |
|
RU2769696C2 |
| BETA-ARYL-ALPHA-HYDROXY-SUBSTITUTED ALKYLCARBOXYLIC ACIDS, METHODS FOR THEIR PREPARING, INTERMEDIATE COMPOUNDS, METHODS FOR THEIR PREPARING, PHARMACEUTICAL COMPOSITION, METHODS FOR TREATMENT OR PROPHYLAXIS OF DISEASES BASED ON NEW COMPOUNDS | 1998 |
|
RU2235094C2 |
| AZA-ARYL-1-H-PYRAZOL-1-YL-SULPHONAMIDES | 2013 |
|
RU2627268C2 |
| SPIRO CONDENSED PYRROLIDINE DERIVATIVES AS INHIBITORS OF DEUBIQUITINATING ENZYMES (DUB) | 2017 |
|
RU2730552C2 |
| NOVEL 2,4,6-TRISUBSTITUTED S-TRIAZINE COMPOUND, A METHOD FOR PRODUCTION THEREOF AND USE THEREOF | 2017 |
|
RU2737085C2 |
| ISOINDOLINE COMPOUND, PRODUCTION METHOD, PHARMACEUTICAL COMPOSITION AND THEIR USE | 2019 |
|
RU2813232C2 |
